NextCure inks ADC deal with Simcere Zaimingnews2025-06-16T14:09:21+00:00June 16th, 2025|Endpoints News|
AstraZeneca, CSPC ink AI drug development deal for $110M upfront news2025-06-13T10:58:25+00:00June 13th, 2025|Endpoints News|
China is closing in on US biotech, Harvard report warnsnews2025-06-05T19:09:12+00:00June 5th, 2025|Endpoints News|
Sagimet touts China partner Ascletis’ Phase 3 FASN inhibitor data in acnenews2025-06-04T15:44:00+00:00June 4th, 2025|Endpoints News|
Regeneron makes $80M obesity deal with Hansohnews2025-06-02T15:11:14+00:00June 2nd, 2025|Endpoints News|
Bristol Myers and BioNTech make $1.5B upfront deal for PD-L1xVEGF cancer drugnews2025-06-02T10:45:32+00:00June 2nd, 2025|Endpoints News|
Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciencesnews2025-05-29T23:30:43+00:00May 29th, 2025|Endpoints News|
TCG’s R&D venture team makes a T cell engager deal with Shanghai biotechnews2025-05-27T10:00:57+00:00May 27th, 2025|Endpoints News|
Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBionews2025-05-20T07:24:02+00:00May 20th, 2025|Endpoints News|
In the Future, China Will Be Dominant. The U.S. Will Be Irrelevant.news2025-05-19T06:19:57+00:00May 19th, 2025|The New York Times|
